posted
news eod. could real nice runner tomorrow.imo
06/19/2006 15:17 EDT China Pharma Holdings Announced Recent Product Approvals
HAIKOU CITY, Hainan Province, China, June 19 /Xinhua-PRNewswire/ -- China Pharma Holdings (OTC Bulletin Board: CPHI) announced that it had recently received approvals from China's State Food and Drug Administration (SFDA) to manufacture and market three new generic products: Ozagrel, Propylgallate and Alginic Sodium Diester. All three drugs are by prescription only and will be available as injectable forms.
About the Products:
Ozagrel is a selective thromboxane A2 (TXA2) synthase inhibitor and has shown potent anti-platelet activities as well as vaso-dilating properties. Ozagrel is indicated for the treatment of acute embolic stroke.
Propyl Gallate has shown to improve blood circulations in coronary artery as well blood-thinning activity in patients. Propyl Gallate is indicated for the prophylaxis and treatment for coronary heart disease, cerebral embolism and thrombophlebitis after surgery.
Alginic Sodium Diester is a semi-synthetic drug derived from seaweed extract. It possesses blood-thinning activities and lipid-lowering activities. Alginic Sodium Diester is approved to be used in patients with ischemic cardiovascular and cerebrovascular diseases, as well as patients with high lipid levels in their blood.
About the diseases:
According to a study conducted by U.S. and Chinese scientists, published recently in the New England Journal of Medicine, vascular diseases and cancer have become the leading causes of death among Chinese adults. Among the top ten diseases that have the highest mortality rate in China in the last decade, cardiovascular diseases and cerebrovascular diseases were ranked first and third, respectively. China's current 60 million obesity population, 20 million diabetes patients and 330 million smokers are among the high-risk groups subject to these diseases.
"Along with China's rapid economic development and the change of people's life style, cardiovascular and cerebrovascular diseases have become the top threat to public health, 2.6 million people die of stoke or heart attack every year in China," commented Ms. Zhi-lin Li, CEO of the company. "With the approvals from SFDA for Ozagrel, Propylgallate and Alginic Sodium Diester, we hope we will further strengthen our market presence in these rising disease areas."
About China Pharma Holdings, Inc.
China Pharma Holdings Inc. is a U.S. public company currently listed on the OTCBB. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty bio-pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. Helpson develops, manufactures, and markets a broad array of generic and brand pharmaceutical products. Helpson's products are marketed in China and are used to fight against Infections, Cardiovascular, CNS and other prevailing diseases.
FORWARD LOOKING STATEMENTS
This release contains certain "forward-looking statements" relating to the business of China Pharma and its subsidiary companies, which can be identified by the use of forward-looking terminology such as "believes, expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties, including all business uncertainties relating to product development, marketing, regulatory actions or delays, the ability to obtain or maintain intellectual property protection, market acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission. China Pharma is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
CONTACT: Donald Xu +1-858-776-8880, dxu*chinapharmaholdings.com
SOURCE China Pharma Holdings
CONTACT: Donald Xu of China Pharma Holdings, +1-858-776-8880, dxu*chinapharmaholdings.com
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
